Lipella Pharmaceuticals Inc. Common Stock reports a Return on Equity (ROE) of -358.28%.

What is LIPO's dividend yield?

Lipella Pharmaceuticals Inc. Common Stock offers a dividend yield of 0.00%.

What is LIPO's Quality Score?

Our AI rates LIPO's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy LIPO?

Our AI Timing Score for LIPO is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does LIPO belong to?

Lipella Pharmaceuticals Inc. Common Stock is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Lipella Pharmaceuticals Inc. (LIPO) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-17 | FS: 2025-09-30)

LIPO AI Analysis Summary

Our AI summary for LIPO: Lipella Pharmaceuticals Inc. Common Stock (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -358.28%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

LIPO

Lipella Pharmaceuticals Inc. Common Stock

US:NASDAQ STOCK Healthcare >> Biotechnology News 76

USD 0.03

-0.03 (-49.38%) Day Change

Watchlist Portfolio Compare Chart

0.03

D/E

-358.3%

ROE

-226.8%

ROA

0.00%

Div Yield

LIPELLA PHARMACEUTICALS INC. COMMON STOCK
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 0.03 Price -0.03 (-49.38%) Day Change	NEWS SCORE: 76

LIPO, the overall quality is not good ( Quality = 15) and the timing to buy is ...(Sign In to See)...

No price data to display chart for the last 3-months of this stock

15 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...

Quality Factors

48%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	76
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	0.03
PBV / Sector	0.10 / 44,105.10 GREAT
Earning Per Share	-1.14

PE / Sector	N/A / 19.37
PEG or PE/Growth / Sector	N/A / 1.06
Average 1M Daily Value	2964.534610000000
Average 1W Daily Value	1642.438440000000

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

47%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-2.46 / 97.23
NPM Average (%) / Sector	-818.98 / -1,697.84
NPM Change Average (%) / Sector	-9.94 / 5,097.59
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-226.82 / 185,260.64
ROA Average (%) / Sector	-135.98 / 36,684.64
ROA Change Average (%) / Sector	52.27 / 422,221.42 GREAT
ROE (%) / Sector	-358.28 / 243,761.81
ROE Average (%) / Sector	-190.62 / 48,758.38
ROE Change Average (%) / Sector	55.45 / 424,967.86 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.42

Registration Details

Analyze Date	2026-08-06 08:00:16
Symbol	LIPO
Name	LIPELLA PHARMACEUTICALS INC. COMMON STOCK
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	4.62 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	0.15 / 9,702.21

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 7800 Susquehanna St., Pittsburgh, PA, United States, 15208

Phone: 412 894 1853

Website: https://lipella.com

Sector: Healthcare >> Biotechnology

Description: Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania. On March 30, 2026, Lipella Pharmaceuticals Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Western District of Pennsylvania.